Search

Your search keyword '"Gridnyev, Oleksiy"' showing total 33 results
Start Over Author "Gridnyev, Oleksiy"
33 results on '"Gridnyev, Oleksiy"'

1. Author Correction: Comparison of the management of Helicobacter pylori infection between the older and younger European populations

Author

Jonaitis, Paulius, Nyssen, Olga P., Saracino, Ilaria Maria, Fiorini, Giulia, Vaira, Dino, Pérez-Aísa, Ángeles, Tepes, Bojan, Castro-Fernandez, Manuel, Pabón-Carrasco, Manuel, Keco-Huerga, Alma, Voynovan, Irina, Lucendo, Alfredo J., Lanas, Ángel, Martínez-Domínguez, Samuel J., Almajano, Enrique Alfaro, Rodrigo, Luis, Vologzanina, Ludmila, Brglez Jurecic, Natasa, Denkovski, Maja, Bujanda, Luis, Mahmudov, Umud, Leja, Mārcis, Lerang, Frode, Babayeva, Gülüstan, Bordin, Dmitry S., Gasbarrini, Antonio, Kupcinskas, Juozas, Gridnyev, Oleksiy, Rokkas, Theodore, Marcos-Pinto, Ricardo, Phull, Perminder S., Smith, Sinead M., Tonkić, Ante, Boltin, Doron, Buzás, György Miklós, Šembera, Štěpán, Şimşek, Halis, Matysiak-Budnik, Tamara, Milivojevic, Vladimir, Marlicz, Wojciech, Venerito, Marino, Boyanova, Lyudmila, Doulberis, Michael, Capelle, Lisette G., Cano-Català, Anna, Moreira, Leticia, Mégraud, Francis, O’Morain, Colm, Gisbert, Javier P., and Jonaitis, Laimas

Published
2023
Full Text
View/download PDF

2. Comparison of the management of Helicobacter pylori infection between the older and younger European populations

Author

Jonaitis, Paulius, Nyssen, Olga P., Saracino, Ilaria Maria, Fiorini, Giulia, Vaira, Dino, Pérez-Aísa, Ángeles, Tepes, Bojan, Castro-Fernandez, Manuel, Pabón-Carrasco, Manuel, Keco-Huerga, Alma, Voynovan, Irina, Lucendo, Alfredo J., Lanas, Ángel, Martínez-Domínguez, Samuel J., Almajano, Enrique Alfaro, Rodrigo, Luis, Vologzanina, Ludmila, Brglez Jurecic, Natasa, Denkovski, Maja, Bujanda, Luis, Mahmudov, Umud, Leja, Mārcis, Lerang, Frode, Babayeva, Gülüstan, Bordin, Dmitry S., Gasbarrini, Antonio, Kupcinskas, Juozas, Gridnyev, Oleksiy, Rokkas, Theodore, Marcos-Pinto, Ricardo, Phull, Perminder S., Smith, Sinead M., Tonkić, Ante, Boltin, Doron, Buzás, György Miklós, Šembera, Štěpán, Şimşek, Halis, Matysiak-Budnik, Tamara, Milivojevic, Vladimir, Marlicz, Wojciech, Venerito, Marino, Boyanova, Lyudmila, Doulberis, Michael, Capelle, Lisette G., Cano-Català, Anna, Moreira, Leticia, Mégraud, Francis, O’Morain, Colm, Gisbert, Javier P., and Jonaitis, Laimas

Published
2023
Full Text
View/download PDF

3. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

Author

Fiorinni, Giulia, Saracino, Ilaria Maria, Carrasco, Manuel Pabon, Huerga, Alma Keco, Almajano, Enrique Alfaro, Martinez Dominguez, Samuel Jesus, Galan, Horacio Alonso, Velayos, Benito, Sadornil, Carmen Dueñas, Botargues Bote, Jose Maria, Gonzalez-Cordero, Pedro Luis, Areia, Miguel, Gomez Rodriguez, Blas Jose, Pellicano, Rinaldo, Nuñez, Óscar, Franceschi, Francesco, Alekseenko, Sergey, Perona, Monica, Abdulkhakov, Rustam, Dominguez-Cajal, Manuel, Notari, Pedro Almela, Camarero, Judith Gomez, Moreno, Manuel Jimenez, Algaba, Alicia, Bermejo, Fernando, Tejada, Javier Tejedor, Susanibar, Elida Oblitas, Boltin, Doron, Georgopoulos, Sotirios, OMorain, Colm, Qasim, Asghar, Beales, Ian, Bakulina, Natalia, Fadeenko, Galina, Malfertheiner, Peter, Rosania, Rosa, Ilchishina, Tatiana, Bogomolov, Pavel, Bakulin, Igor, Zaytsev, Oleg, Gravina, Antonietta Gerarda, Romano, Marco, Di Leo, Alfredo, Losurdo, Giuseppe, Grigorieva, Ludmila, Guillena, Pedro Delgado, Marusic, Marinko, Jurcic, Dragan, Dekhnich, Natalia Nikolaevna, Iyo, Eduardo, de la Peña Negro, Luisa Carmen, Baryshnikova, Natalia, Bakanova, Natalia, Simsek, Halis, Simsek, Cem, Gridnyev, Oleksiy, Fernandez-Bermejo, Miguel, Angueira, Teresa, Ruiz-Zorrilla Lopez, Rafael, Gomez, Barbara, Kovacheva-Slavova, Mila, Lahat, Adi, Alcedo, Javier, Campillo, Ana, Belousova, Liya Nikolaevna, Villarroya, Ramon Pajares, Ljubicic, Neven, Nikolic, Marko, González-Santiago, Jesús M., Santamaría, Diego Burgos, Pakhomova, Anna, Sekulic-Spasic, Izabela, Ghisa, Matteo, Farinati, Fabio, Sagdati, Sabir Irfan, Panic, Nikola, Heluwaert, Frederic, Amorena, Edurne, Moreira, Leticia, Esparrach, Gloria Fernandez, Plotnikova, Ekaterina Yuryevna, Kukla, Michal, Kamburov, Victor, Lamuela Calvo, Luis Javier, Rankovic, Ivan, Lavín, Antonio Cuadrado, Lazaro, Yolanda Arguedas, Carrera Agnieszka Dobrowolska, Victor Gonzalez, Eder, Piotr, Kononova, Alla, Nyssen, Olga P., Vaira, Dino, Pérez Aísa, Ángeles, Rodrigo, Luis, Castro-Fernandez, Manuel, Jonaitis, Laimas, Tepes, Bojan, Vologzhanina, Liudmila, Caldas, María, Lanas, Angel, Lucendo, Alfredo J., Bujanda, Luis, Ortuño, Juan, Barrio, Jesús, Huguet, Jose M., Voynovan, Irina, Lasala, Jorge Perez, Sarsenbaeva, Aiman Silkanovna, Fernandez-Salazar, Luis, Molina-Infante, Javier, Jurecic, Natasa Brglez, Gasbarrini, Antonio, Kupčinskas, Juozas, Bordin, Dmitry, Marcos-Pinto, Ricardo, Lerang, Frode, Leja, Marcis, Buzas, Gyorgy M., Niv, Yaron, Rokkas, Theodore, Phull, Perminder, Smith, Sinead, Shvets, Oleg, Venerito, Marino, Milivojevic, Vladimir, Simsek, Ilkay, Lamy, Vincent, Bytzer, Peter, Boyanova, Lyudmila, Kunovský, Lumír, Beglinger, Christoph, Doulberis, Michael, Marlicz, Wojciech, Goldis, Adrian, Tonkić, Ante, Capelle, Lisette, Puig, Ignasi, Megraud, Francis, Morain, Colm O’, and Gisbert, Javier P.

Published
2022
Full Text
View/download PDF

4. Role of compliance in Helicobacter pylorieradication treatment: Results of the European Registry on H. pylorimanagement

Author

Huguet, Jose M., Ferrer‐Barceló, Luis, Suárez, Patrícia, Barcelo‐Cerda, Susana, Sempere, Javier, Saracino, Ilaria Maria, Fiorini, Giulia, Vaira, Dino, Pérez‐Aísa, Ángeles, Jonaitis, Laimas, Tepes, Bojan, Castro‐Fernandez, M., Pabón‐Carrasco, Manuel, Keco‐Huerga, Alma, Voynovan, Irina, Lucendo, Alfredo J., Lanas, Ángel, Martínez‐Domínguez, Samuel J., Alfaro Almajano, Enrique, Rodrigo, Luis, Vologzanina, Ludmila, Bordin, Dmitry S., Gasbarrini, Antonio, Babayeva, Gülüstan, Lerang, Frode, Leja, Mārcis, Kupčinskas, Juozas, Rokkas, Theodore, Marcos‐Pinto, Ricardo, Meštrović, Antonio, Gridnyev, Oleksiy, Phull, Perminder S., Smith, Sinead M., Boltin, Doron, Buzás, György Miklós, Kral, Jan, Şimşek, Halis, Matysiak‐Budnik, Tamara, Milivojevic, Vladimir, Marlicz, Wojciech, Venerito, Marino, Boyanova, Lyudmila, Doulberis, Michael, Capelle, Lisette G., Cano‐Català, Anna, Moreira, Leticia, Nyssen, Olga P., Mégraud, Francis, O’Morain, Colm, and Gisbert, Javier P.

Abstract

Adherence to Helicobacter pylori (H. pylori)eradication treatment is a cornerstone for achieving adequate treatment efficacy. To determine which factors influence compliance with treatment. A systematic prospective non‐interventional registry (Hp‐EuReg) of the clinical practice of European gastroenterologists. Compliance was considered adequate if ≥90% drug intake. Data were collected until September 2021 using the AEG‐REDCap e‐CRF and were subjected to quality control. Modified intention‐to‐treat analyses were performed. Multivariate analysis carried out the factors associated with the effectiveness of treatment and compliance. Compliance was inadequate in 646 (1.7%) of 38,698 patients. The non‐compliance rate was higher in patients prescribed longer regimens (10‐, 14‐days) and rescue treatments, patients with uninvestigated dyspepsia/functional dyspepsia, and patients reporting adverse effects. Prevalence of non‐adherence was lower for first‐line treatment than for rescue treatment (1.5% vs. 2.2%; p< 0.001). Differences in non‐adherence in the three most frequent first‐line treatments were shown: 1.1% with proton pump inhibitor + clarithromycin + amoxicillin; 2.3% with proton pump inhibitor clarithromycin amoxicillin metronidazole; and 1.8% with bismuth quadruple therapy. These treatments were significantly more effective in compliant than in non‐compliant patients: 86% versus 44%, 90% versus 71%, and 93% versus 64%, respectively (p< 0.001). In the multivariate analysis, the variable most significantly associated with higher effectiveness was adequate compliance (odds ratio, 6.3 [95%CI, 5.2–7.7]; p< 0.001). Compliance with Helicobacter pylorieradication treatment is very good. Factors associated with poor compliance include uninvestigated/functional dyspepsia, rescue‐treatment, prolonged treatment regimens, the presence of adverse events, and the use of non‐bismuth sequential and concomitant treatment. Adequate treatment compliance was the variable most closely associated with successful eradication.

Published
2024
Full Text
View/download PDF

5. 131 - PAUTAS Y EFECTIVIDAD DE LAS TERAPIAS CUÁDRUPLES CON BISMUTO EN EUROPA: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Calvet, Xavier, primary, Gené, Emili, additional, Olmedo, Llum, additional, Bordin, Dmitry, additional, García-Morales, Natalia, additional, Hernández, Luis, additional, Gridnyev, Oleksiy, additional, Kupinskas, Juozas, additional, Gasbarrini, Antonio, additional, Boltin, Doron, additional, Babayeva, Gulustan, additional, Pinto, Ricardo Marcos, additional, Tepes, Bojan, additional, Buzas, Gyorgy M, additional, Papp, Veronika, additional, Simsek, Halis, additional, Cano-Català, Anna, additional, Moreira, Leticia, additional, Puig, Ignasi, additional, Nyssen, Olga P., additional, Mégraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional

Published
2023
Full Text
View/download PDF

6. PAPEL DEL USO DE PROBIÓTICOS EN LA EFECTIVIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Casas, Diego, primary, Alcedo, Javier, additional, Lafuente, Miguel, additional, López, F. Javier, additional, Pérez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Saracino, Ilaria Maria, additional, Tepes, Bojan, additional, Jonaitis, Laimas, additional, Castro-Fernández, Manuel, additional, Carrasco, Manuel Pabón, additional, Huerga, Alma Keco-, additional, Voynovan, Irina, additional, Bujanda, Luis, additional, Lucendo, Alfredo J., additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Phull, Perminder S., additional, Rodrigo, Luis, additional, Lanas, Angel, additional, Martínez-Domínguez, Samuel J., additional, Alfaro, Enrique, additional, Fadieienko, Galina D, additional, Huguet, José M., additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupcinskas, Juozas, additional, Babayeva, Gülüstan, additional, Gridnyev, Oleksiy, additional, Leja, Mrcis, additional, Rokkas, Theodore, additional, Marcos-Pinto, Ricardo, additional, Lerang, Frode, additional, Boltin, Doron, additional, Papp, Veronika, additional, Tonki, Ante, additional, Smith, Sinead M., additional, Simsek, Halis, additional, Venerito, Marino, additional, Boyanova, Lyudmila, additional, Milivojevic, Vladimir, additional, Kunovsky, Lumir, additional, Matysiak-Budnik, Tamara, additional, Marlicz, Wojciech, additional, Doulberis, Michael, additional, Cano-Català, Anna, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, Morain, Colm O., additional, and Gisbert, Javier P., additional

Published
2023
Full Text
View/download PDF

7. 135 - TENDENCIAS DE PRESCRIPCIÓN DE TRATAMIENTOS ERRADICADORES Y DE SU EFECTIVIDAD EN PACIENTES NAÏVE A LO LARGO DE 10 AÑOS (2013-2022) EN EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Nyssen, Olga P., primary, Jonaitis, Laimas, additional, Pérez-Aísa, Ángeles, additional, Vaira, Dino, additional, Fiorini, Giulia, additional, Saracino, Ilaria Maria, additional, Tepes, Bojan, additional, Bordin, Dmitry, additional, Huerga, Alma Keco-, additional, Castro-Fernández, Manuel, additional, Lucendo, Alfredo, additional, Vologzhanina, Liudmila, additional, Bujanda, Luis, additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Lanas, Angel, additional, Martínez-Dominguez, Samuel, additional, Alfaro, Enrique, additional, Leja, Marcis, additional, Bumane, Renate, additional, Mammadov, Emin, additional, Babayeva, Gulustan, additional, Mahmudov, Umud, additional, Caldas, María, additional, Rodrigo, Luis, additional, Lerang, Frode, additional, Fadieienko, Galyna, additional, Abdulkhakov, Rustam, additional, Malavés, Jose María Huguet, additional, Zaytsev, Oleg, additional, Ilchishina, Tatiana, additional, Fernández-Salazar, Luis, additional, Alcaide, Noelia, additional, Velayos, Benito, additional, Sarsenbaeva, Aiman Silkanovna, additional, Bakulin, Igor, additional, Gravina, Antonietta G., additional, Romano, Marco, additional, Perona, Mónica, additional, Alekseenko, Sergey, additional, Barrio, Jesús, additional, Areia, Miguel, additional, Nuñez, Óscar, additional, Bogomolov, Pavel, additional, Rodríguez, Blas José Gómez, additional, Cajal, Manuel Dominguez-, additional, Camarero, Judith Gomez, additional, Moreno, Manuel Jiménez, additional, Georgopoulos, Sotirios, additional, Notari, Pedro Almela, additional, Tonkic, Ante, additional, Pellicano, Rinaldo, additional, Simsek, Halis, additional, Kunovský, Lumír, additional, Gasbarrini, Antonio, additional, Bote, Jose Maria Botargues, additional, Buzas, Gyorgy M, additional, Fernández-Bermejo, Miguel, additional, Phull, Perminder, additional, Venerito, Marino, additional, Malfertheiner, Peter, additional, Rosania, Rosa, additional, Link, Alexander, additional, Iyo, Eduardo, additional, Kupinskas, Juozas, additional, Shvets, Oleg, additional, Pinto, Ricardo Marcos, additional, Rokkas, Theodore, additional, Simsek, Ilkay, additional, Smith, Sinead, additional, Boltin, Doron, additional, Lamarque, Dominique, additional, Dobru, Daniela, additional, Marlicz, Wojciech, additional, Milivojevic, Vladimir, additional, Boyanova, Lyudmila, additional, Lamy, Vincent, additional, Doulberis, Michael, additional, Bytzer, Peter, additional, Capelle, Lisette, additional, Gridnyev, Oleksiy, additional, Ristimaki, Ari, additional, Cano-Català, Anna, additional, Puig, Ignasi, additional, Mégraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional

Published
2023
Full Text
View/download PDF

8. 130 - COMPARACIÓN DE LA EFECTIVIDAD DE LOS TRATAMIENTOS ERRADICADORES MÁS FRECUENTES ENTRE LAS POBLACIONES MÁS MAYORES Y MÁS JÓVENES DE EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Jonaitis, Paulius, primary, Nyssen, Olga P., additional, Saracino, Ilaria Maria, additional, Fiorini, Giulia, additional, Vaira, Dino, additional, Pérez-Aísa, Ángeles, additional, Tepes, Bojan, additional, Castro-Fernández, M., additional, Pabón-Carrasco, Manuel, additional, Keco-Huerga, Alma, additional, Voynovan, Irina, additional, Lucendo, Alfredo J, additional, Lanas, Ángel, additional, Martínez-Domínguez, Samuel J, additional, Almajano, Enrique Alfaro, additional, Rodrigo, Luis, additional, Vologzanina, Ludmila, additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Bujanda, Luis, additional, Mahmudov, Umud, additional, Leja, Mrcis, additional, Lerang, Frode, additional, Babayeva, Gülüstan, additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupcinskas, Juozas, additional, Gridnyev, Oleksiy, additional, Rokkas, Theodore, additional, Marcos-Pinto, Ricardo, additional, Phull, Perminder S., additional, Smith, Sinead M., additional, Tonki, Ante, additional, Boltin, Doron, additional, Buzás, György Miklós, additional, Kunovský, Lumír, additional, imek, Halis, additional, Matysiak-Budnik, Tamara, additional, Milivojevic, Vladimir, additional, Marlicz, Wojciech, additional, Venerito, Marino, additional, Boyanova, Lyudmila, additional, Doulberis, Michael, additional, Capelle, Lisette G., additional, Cano-Català, Anna, additional, Moreira, Leticia, additional, Mégraud, Francis, additional, O’Morain, Colm, additional, Gisbert, Javier P., additional, and Jonaitis, Laimas, additional

Published
2023
Full Text
View/download PDF

9. 127 - IMPACTO DEL USO DE PROBIÓTICOS EN LA SEGURIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Casas, Diego, primary, Alcedo, Javier, additional, Lafuente, Miguel, additional, López, F. Javier, additional, Pérez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Saracino, Ilaria Maria, additional, Tepes, Bojan, additional, Jonaitis, Laimas, additional, Castro-Fernández, Manuel, additional, Pabón-Carrasco, Manuel, additional, Keco-Huerga, Alma, additional, Voynovan, Irina, additional, Bujanda, Luis, additional, Lucendo, Alfredo J., additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Phull, Perminder S., additional, Rodrigo, Luis, additional, Lanas, Angel, additional, Martínez-Domínguez, Samuel J., additional, Alfaro, Enrique, additional, Fadieienko, Galina D., additional, Huguet, Jose M., additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupcinskas, Juozas, additional, Babayeva, Gülüstan, additional, Gridnyev, Oleksiy, additional, Leja, Mrcis, additional, Rokkas, Theodore, additional, Marcos-Pinto, Ricardo, additional, Lerang, Frode, additional, Boltin, Doron, additional, Papp, Veronika, additional, Tonki, Ante, additional, Smith, Sinead M., additional, Simsek, Halis, additional, Venerito, Marino, additional, Boyanova, Lyudmila, additional, Milivojevic, Vladimir, additional, Kunovsky, Lumir, additional, Matysiak-Budnik, Tamara, additional, Marlicz, Wojciech, additional, Doulberis, Michael, additional, Cano-Català, Anna, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, Morain, Colm O., additional, and Gisbert, Javier P., additional

Published
2023
Full Text
View/download PDF

10. 133 - PATRÓN DE PRESCRIPCIÓN DE PROBIÓTICOS ADYUVANTES A LA TERAPIA ERRADICADORA FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Casas, Diego, primary, Alcedo, Javier, additional, Lafuente, Miguel, additional, López, F. Javier, additional, Pérez-Aisa, Angeles, additional, Pavoni, Matteo, additional, Saracino, Ilaria Maria, additional, Tepes, Bojan, additional, Jonaitis, Laimas, additional, Castro-Fernández, Manuel, additional, Pabón-Carrasco, Manuel, additional, Keco-Huerga, Alma, additional, Voynovan, Irina, additional, Bujanda, Luis, additional, Lucendo, Alfredo J., additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Phull, Perminder S., additional, Rodrigo, Luis, additional, Lanas, Angel, additional, Martínez-Domínguez, Samuel J., additional, Alfaro, Enrique, additional, Fadieienko, Galina D, additional, Huguet, José M., additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupcinskas, Juozas, additional, Babayeva, Gülüstan, additional, Gridnyev, Oleksiy, additional, Leja, Mrcis, additional, Rokkas, Theodore, additional, Marcos-Pinto, Ricardo, additional, Lerang, Frode, additional, Boltin, Doron, additional, Papp, Veronika, additional, Tonki, Ante, additional, Smith, Sinead M., additional, Simsek, Halis, additional, Venerito, Marino, additional, Boyanova, Lyudmila, additional, Milivojevic, Vladimir, additional, Kunovsky, Lumir, additional, Matysiak-Budnik, Tamara, additional, Marlicz, Wojciech, additional, Doulberis, Michael, additional, Cano-Català, Anna, additional, Hernández, Luis, additional, Moreira, Leticia, additional, Nyssen, Olga P., additional, Megraud, Francis, additional, Morain, Colm O., additional, and Gisbert, Javier P., additional

Published
2023
Full Text
View/download PDF

11. Empirical rescue treatment ofHelicobacter pyloriinfection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry onH. pylorimanagement (Hp-EuReg)

Author

Burgos-Santamaría, Diego, primary, Nyssen, Olga P, additional, Gasbarrini, Antonio, additional, Vaira, Dino, additional, Pérez-Aisa, Ángeles, additional, Rodrigo, Luís, additional, Pellicano, Rinaldo, additional, Keco-Huerga, Alma, additional, Pabón-Carrasco, Manuel, additional, Castro-Fernandez, Manuel, additional, Boltin, Doron, additional, Barrio, Jesus, additional, Phull, Perminder, additional, Kupcinskas, Juozas, additional, Jonaitis, Laimas, additional, Ortiz-Polo, Inmaculada, additional, Tepes, Bojan, additional, Lucendo, Alfredo J, additional, Huguet, José María, additional, Areia, Miguel, additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Bujanda, Luís, additional, Ramos-San Román, June, additional, Cuadrado-Lavín, Antonio, additional, Gomez-Camarero, Judith, additional, Jiménez Moreno, Manuel Alfonso, additional, Lanas, Angel, additional, Martinez-Dominguez, Samuel Jesús, additional, Alfaro, Enrique, additional, Marcos-Pinto, Ricardo, additional, Milivojevic, Vladimir, additional, Rokkas, Theodore, additional, Leja, Marcis, additional, Smith, Sinead, additional, Tonkić, Ante, additional, Buzás, György Miklós, additional, Doulberis, Michael, additional, Venerito, Marino, additional, Lerang, Frode, additional, Bordin, Dmitry S, additional, Lamy, Vincent, additional, Capelle, Lisette G, additional, Marlicz, Wojciech, additional, Dobru, Daniela, additional, Gridnyev, Oleksiy, additional, Puig, Ignasi, additional, Mégraud, Francis, additional, O'Morain, Colm, additional, and Gisbert, Javier P, additional

Published
2022
Full Text
View/download PDF

12. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

Author

Nyssen, Olga P., primary, Vaira, Dino, additional, Pérez Aísa, Ángeles, additional, Rodrigo, Luis, additional, Castro-Fernandez, Manuel, additional, Jonaitis, Laimas, additional, Tepes, Bojan, additional, Vologzhanina, Liudmila, additional, Caldas, María, additional, Lanas, Angel, additional, Lucendo, Alfredo J., additional, Bujanda, Luis, additional, Ortuño, Juan, additional, Barrio, Jesús, additional, Huguet, Jose M., additional, Voynovan, Irina, additional, Lasala, Jorge Perez, additional, Sarsenbaeva, Aiman Silkanovna, additional, Fernandez-Salazar, Luis, additional, Molina-Infante, Javier, additional, Jurecic, Natasa Brglez, additional, Areia, Miguel, additional, Gasbarrini, Antonio, additional, Kupčinskas, Juozas, additional, Bordin, Dmitry, additional, Marcos-Pinto, Ricardo, additional, Lerang, Frode, additional, Leja, Marcis, additional, Buzas, Gyorgy M., additional, Niv, Yaron, additional, Rokkas, Theodore, additional, Phull, Perminder, additional, Smith, Sinead, additional, Shvets, Oleg, additional, Venerito, Marino, additional, Milivojevic, Vladimir, additional, Simsek, Ilkay, additional, Lamy, Vincent, additional, Bytzer, Peter, additional, Boyanova, Lyudmila, additional, Kunovský, Lumír, additional, Beglinger, Christoph, additional, Doulberis, Michael, additional, Marlicz, Wojciech, additional, Goldis, Adrian, additional, Tonkić, Ante, additional, Capelle, Lisette, additional, Puig, Ignasi, additional, Megraud, Francis, additional, Morain, Colm O’, additional, Gisbert, Javier P., additional, Fiorinni, Giulia, additional, Saracino, Ilaria Maria, additional, Carrasco, Manuel Pabon, additional, Huerga, Alma Keco, additional, Almajano, Enrique Alfaro, additional, Martinez Dominguez, Samuel Jesus, additional, Galan, Horacio Alonso, additional, Velayos, Benito, additional, Sadornil, Carmen Dueñas, additional, Botargues Bote, Jose Maria, additional, Gonzalez-Cordero, Pedro Luis, additional, Gomez Rodriguez, Blas Jose, additional, Pellicano, Rinaldo, additional, Nuñez, Óscar, additional, Franceschi, Francesco, additional, Alekseenko, Sergey, additional, Perona, Monica, additional, Abdulkhakov, Rustam, additional, Dominguez-Cajal, Manuel, additional, Notari, Pedro Almela, additional, Camarero, Judith Gomez, additional, Moreno, Manuel Jimenez, additional, Algaba, Alicia, additional, Bermejo, Fernando, additional, Tejada, Javier Tejedor, additional, Susanibar, Elida Oblitas, additional, Boltin, Doron, additional, Georgopoulos, Sotirios, additional, OMorain, Colm, additional, Qasim, Asghar, additional, Beales, Ian, additional, Bakulina, Natalia, additional, Fadeenko, Galina, additional, Malfertheiner, Peter, additional, Rosania, Rosa, additional, Ilchishina, Tatiana, additional, Bogomolov, Pavel, additional, Bakulin, Igor, additional, Zaytsev, Oleg, additional, Gravina, Antonietta Gerarda, additional, Romano, Marco, additional, Di Leo, Alfredo, additional, Losurdo, Giuseppe, additional, Grigorieva, Ludmila, additional, Guillena, Pedro Delgado, additional, Marusic, Marinko, additional, Jurcic, Dragan, additional, Dekhnich, Natalia Nikolaevna, additional, Iyo, Eduardo, additional, de la Peña Negro, Luisa Carmen, additional, Baryshnikova, Natalia, additional, Bakanova, Natalia, additional, Simsek, Halis, additional, Simsek, Cem, additional, Gridnyev, Oleksiy, additional, Fernandez-Bermejo, Miguel, additional, Angueira, Teresa, additional, Ruiz-Zorrilla Lopez, Rafael, additional, Gomez, Barbara, additional, Kovacheva-Slavova, Mila, additional, Lahat, Adi, additional, Alcedo, Javier, additional, Campillo, Ana, additional, Belousova, Liya Nikolaevna, additional, Villarroya, Ramon Pajares, additional, Ljubicic, Neven, additional, Nikolic, Marko, additional, González-Santiago, Jesús M., additional, Santamaría, Diego Burgos, additional, Pakhomova, Anna, additional, Sekulic-Spasic, Izabela, additional, Ghisa, Matteo, additional, Farinati, Fabio, additional, Sagdati, Sabir Irfan, additional, Panic, Nikola, additional, Heluwaert, Frederic, additional, Amorena, Edurne, additional, Moreira, Leticia, additional, Esparrach, Gloria Fernandez, additional, Plotnikova, Ekaterina Yuryevna, additional, Kukla, Michal, additional, Kamburov, Victor, additional, Lamuela Calvo, Luis Javier, additional, Rankovic, Ivan, additional, Lavín, Antonio Cuadrado, additional, Lazaro, Yolanda Arguedas, additional, Carrera Agnieszka Dobrowolska, Victor Gonzalez, additional, Eder, Piotr, additional, and Kononova, Alla, additional

Published
2022
Full Text
View/download PDF

13. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)

Author

Burgos-Santamaría, Diego, Nyssen, Olga P, Gasbarrini, Antonio, Vaira, Dino, Pérez-Aisa, Ángele, Rodrigo, Luí, Pellicano, Rinaldo, Keco-Huerga, Alma, Pabón-Carrasco, Manuel, Castro-Fernandez, Manuel, Boltin, Doron, Barrio, Jesu, Phull, Perminder, Kupcinskas, Juoza, Jonaitis, Laima, Ortiz-Polo, Inmaculada, Tepes, Bojan, Lucendo, Alfredo J, Huguet, José María, Areia, Miguel, Jurecic, Natasa Brglez, Denkovski, Maja, Bujanda, Luí, Ramos-San Román, June, Cuadrado-Lavín, Antonio, Gomez-Camarero, Judith, Jiménez Moreno, Manuel Alfonso, Lanas, Angel, Martinez-Dominguez, Samuel Jesú, Alfaro, Enrique, Marcos-Pinto, Ricardo, Milivojevic, Vladimir, Rokkas, Theodore, Leja, Marci, Smith, Sinead, Tonkić, Ante, Buzás, György Mikló, Doulberis, Michael, Venerito, Marino, Lerang, Frode, Bordin, Dmitry S, Lamy, Vincent, Capelle, Lisette G, Marlicz, Wojciech, Dobru, Daniela, Gridnyev, Oleksiy, Puig, Ignasi, Mégraud, Franci, O'Morain, Colm, Gisbert, Javier P, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Burgos-Santamaría, Diego, Nyssen, Olga P, Gasbarrini, Antonio, Vaira, Dino, Pérez-Aisa, Ángele, Rodrigo, Luí, Pellicano, Rinaldo, Keco-Huerga, Alma, Pabón-Carrasco, Manuel, Castro-Fernandez, Manuel, Boltin, Doron, Barrio, Jesu, Phull, Perminder, Kupcinskas, Juoza, Jonaitis, Laima, Ortiz-Polo, Inmaculada, Tepes, Bojan, Lucendo, Alfredo J, Huguet, José María, Areia, Miguel, Jurecic, Natasa Brglez, Denkovski, Maja, Bujanda, Luí, Ramos-San Román, June, Cuadrado-Lavín, Antonio, Gomez-Camarero, Judith, Jiménez Moreno, Manuel Alfonso, Lanas, Angel, Martinez-Dominguez, Samuel Jesú, Alfaro, Enrique, Marcos-Pinto, Ricardo, Milivojevic, Vladimir, Rokkas, Theodore, Leja, Marci, Smith, Sinead, Tonkić, Ante, Buzás, György Mikló, Doulberis, Michael, Venerito, Marino, Lerang, Frode, Bordin, Dmitry S, Lamy, Vincent, Capelle, Lisette G, Marlicz, Wojciech, Dobru, Daniela, Gridnyev, Oleksiy, Puig, Ignasi, Mégraud, Franci, O'Morain, Colm, Gisbert, Javier P, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

Objective To evaluate the use, effectiveness and safety of Helicobacter pylori empirical rescue therapy in third and subsequent treatment lines in Europe. Design International, prospective, non-interventional registry of the clinical practice of European gastroenterologists. Data were collected and quality reviewed until October 2021 at Asociacion Espanola de Gastroenterologia-Research Electronic Data Capture. All cases with three or more empirical eradication attempts were assessed for effectiveness by modified intention-to-treat and per-protocol analysis. Results Overall, 2144 treatments were included: 1519, 439, 145 and 41 cases from third, fourth, fifth and sixth treatment lines, respectively. Sixty different therapies were used; the 15 most frequently prescribed encompassed > 90% of cases. Overall effectiveness remained < 90% in all therapies. Optimised treatments achieved a higher eradication rate than non-optimised (78% vs 67%, p < 0.0001). From 2017 to 2021, only 44% of treatments other than 10-day single-capsule therapy used high proton-pump inhibitor doses and lasted & GE;14 days. Quadruple therapy containing metronidazole, tetracycline and bismuth achieved optimal eradication rates only when prescribed as third-line treatment, either as 10-day single-capsule therapy (87%) or as 14-day traditional therapy with tetracycline hydrochloride (95%). Triple amoxicillin-levofloxacin therapy achieved 90% effectiveness in Eastern Europe only or when optimised. The overall incidence of adverse events was 31%. Conclusion Empirical rescue treatment in third and subsequent lines achieved suboptimal effectiveness in most European regions. Only quadruple bismuth-metronidazole-tetracycline (10-day single-capsule or 14-day traditional scheme) and triple amoxicillin-levofloxacin therapies reached acceptable outcomes in some settings. Compliance with empirical therapy optimisation principles is still poor 5 years after clinical practice guidelines update.

Published
2022

16. A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group

Author

Keller, Josbert J., Ooijevaar, Rogier E., Hvas, Christian L., Terveer, Elisabeth M., Lieberknecht, Simone C., Hogenauer, Christoph, Arkkila, Perttu, Sokol, Harry, Gridnyev, Oleksiy, Megraud, Francis, Kump, Patrizia K., Nakov, Radislav, Goldenberg, Simon D., Satokari, Reetta, Tkatch, Sergiy, Sanguinetti, Maurizio, Cammarota, Giovanni, Dorofeev, Andrey, Gubska, Olena, Laniro, Gianluca, Mattila, Eero, Arasaradnam, Ramesh P., Sarin, Shiv K., Sood, Ajit, Putignani, Lorenza, Alric, Laurent, Baunwall, Simon M. D., Kupcinskas, Juozas, Link, Alexander, Goorhuis, Abraham G., Verspaget, Hein W., Ponsioen, Cyriel, Hold, Georgina L., Tilg, Herbert, Kassam, Zain, Kuijper, Ed J., Gasbarrini, Antonio, Mulder, Chris J. J., Williams, Horace R. T., Vehreschild, Maria J. G. T., Keller, Josbert J., Ooijevaar, Rogier E., Hvas, Christian L., Terveer, Elisabeth M., Lieberknecht, Simone C., Hogenauer, Christoph, Arkkila, Perttu, Sokol, Harry, Gridnyev, Oleksiy, Megraud, Francis, Kump, Patrizia K., Nakov, Radislav, Goldenberg, Simon D., Satokari, Reetta, Tkatch, Sergiy, Sanguinetti, Maurizio, Cammarota, Giovanni, Dorofeev, Andrey, Gubska, Olena, Laniro, Gianluca, Mattila, Eero, Arasaradnam, Ramesh P., Sarin, Shiv K., Sood, Ajit, Putignani, Lorenza, Alric, Laurent, Baunwall, Simon M. D., Kupcinskas, Juozas, Link, Alexander, Goorhuis, Abraham G., Verspaget, Hein W., Ponsioen, Cyriel, Hold, Georgina L., Tilg, Herbert, Kassam, Zain, Kuijper, Ed J., Gasbarrini, Antonio, Mulder, Chris J. J., Williams, Horace R. T., and Vehreschild, Maria J. G. T.

Abstract

Background Faecal microbiota transplantation is an emerging therapeutic option, particularly for the treatment of recurrent Clostridioides difficile infection. Stool banks that organise recruitment and screening of faeces donors are being embedded within the regulatory frameworks described in the European Union Tissue and Cells Directive and the technical guide to the quality and safety of tissue and cells for human application, published by the European Council. Objective Several European and international consensus statements concerning faecal microbiota transplantation have been issued. While these documents provide overall guidance, we aim to provide a detailed description of all processes that relate to the collection, handling and clinical application of human donor stool in this document. Methods Collaborative subgroups of experts on stool banking drafted concepts for all domains pertaining to stool banking. During a working group meeting in the United European Gastroenterology Week 2019 in Barcelona, these concepts were discussed and finalised to be included in our overall guidance document about faecal microbiota transplantation. Results A guidance document for all domains pertaining to stool banking was created. This document includes standard operating manuals for several processes involved with stool banking, such as handling of donor material, storage and donor screening. Conclusion The implementation of faecal microbiota transplantation by stool banks in concordance with our guidance document will enable quality assurance and guarantee the availability of donor faeces preparations for patients.

Published
2021

17. Empirical rescue treatment of Helicobacter pyloriinfection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylorimanagement (Hp-EuReg)

Author

Burgos-Santamaría, Diego, Nyssen, Olga P, Gasbarrini, Antonio, Vaira, Dino, Pérez-Aisa, Ángeles, Rodrigo, Luís, Pellicano, Rinaldo, Keco-Huerga, Alma, Pabón-Carrasco, Manuel, Castro-Fernandez, Manuel, Boltin, Doron, Barrio, Jesus, Phull, Perminder, Kupcinskas, Juozas, Jonaitis, Laimas, Ortiz-Polo, Inmaculada, Tepes, Bojan, Lucendo, Alfredo J, Huguet, José María, Areia, Miguel, Jurecic, Natasa Brglez, Denkovski, Maja, Bujanda, Luís, Ramos-San Román, June, Cuadrado-Lavín, Antonio, Gomez-Camarero, Judith, Jiménez Moreno, Manuel Alfonso, Lanas, Angel, Martinez-Dominguez, Samuel Jesús, Alfaro, Enrique, Marcos-Pinto, Ricardo, Milivojevic, Vladimir, Rokkas, Theodore, Leja, Marcis, Smith, Sinead, Tonkić, Ante, Buzás, Gyo¨rgy Miklós, Doulberis, Michael, Venerito, Marino, Lerang, Frode, Bordin, Dmitry S, Lamy, Vincent, Capelle, Lisette G, Marlicz, Wojciech, Dobru, Daniela, Gridnyev, Oleksiy, Puig, Ignasi, Mégraud, Francis, O'Morain, Colm, and Gisbert, Javier P

Abstract

ObjectiveTo evaluate the use, effectiveness and safety of Helicobacter pyloriempirical rescue therapy in third and subsequent treatment lines in Europe.DesignInternational, prospective, non-interventional registry of the clinical practice of European gastroenterologists. Data were collected and quality reviewed until October 2021 at Asociación Española de Gastroenterología-Research Electronic Data Capture. All cases with three or more empirical eradication attempts were assessed for effectiveness by modified intention-to-treat and per-protocol analysis.ResultsOverall, 2144 treatments were included: 1519, 439, 145 and 41 cases from third, fourth, fifth and sixth treatment lines, respectively. Sixty different therapies were used; the 15 most frequently prescribed encompassed >90% of cases. Overall effectiveness remained <90% in all therapies. Optimised treatments achieved a higher eradication rate than non-optimised (78% vs 67%, p<0.0001). From 2017 to 2021, only 44% of treatments other than 10-day single-capsule therapy used high proton-pump inhibitor doses and lasted ≥14 days. Quadruple therapy containing metronidazole, tetracycline and bismuth achieved optimal eradication rates only when prescribed as third-line treatment, either as 10-day single-capsule therapy (87%) or as 14-day traditional therapy with tetracycline hydrochloride (95%). Triple amoxicillin-levofloxacin therapy achieved 90% effectiveness in Eastern Europe only or when optimised. The overall incidence of adverse events was 31%.ConclusionEmpirical rescue treatment in third and subsequent lines achieved suboptimal effectiveness in most European regions. Only quadruple bismuth-metronidazole-tetracycline (10-day single-capsule or 14-day traditional scheme) and triple amoxicillin-levofloxacin therapies reached acceptable outcomes in some settings. Compliance with empirical therapy optimisation principles is still poor 5 years after clinical practice guidelines update.Trial registration numberNCT02328131.

Published
2023
Full Text
View/download PDF

18. A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group

Author

Keller, Josbert J., primary, Ooijevaar, Rogier E., additional, Hvas, Christian L., additional, Terveer, Elisabeth M., additional, Lieberknecht, Simone C., additional, Högenauer, Christoph, additional, Arkkila, Perttu, additional, Sokol, Harry, additional, Gridnyev, Oleksiy, additional, Mégraud, Francis, additional, Kump, Patrizia K., additional, Nakov, Radislav, additional, Goldenberg, Simon D., additional, Satokari, Reetta, additional, Tkatch, Sergiy, additional, Sanguinetti, Maurizio, additional, Cammarota, Giovanni, additional, Dorofeev, Andrey, additional, Gubska, Olena, additional, Ianiro, Gianluca, additional, Mattila, Eero, additional, Arasaradnam, Ramesh P., additional, Sarin, Shiv K., additional, Sood, Ajit, additional, Putignani, Lorenza, additional, Alric, Laurent, additional, Baunwall, Simon M. D., additional, Kupcinskas, Juozas, additional, Link, Alexander, additional, Goorhuis, Abraham G., additional, Verspaget, Hein W., additional, Ponsioen, Cyriel, additional, Hold, Georgina L., additional, Tilg, Herbert, additional, Kassam, Zain, additional, Kuijper, Ed J., additional, Gasbarrini, Antonio, additional, Mulder, Chris J. J., additional, Williams, Horace R. T., additional, and Vehreschild, Maria J. G. T., additional

Published
2021
Full Text
View/download PDF

19. sj-pdf-1-ueg-10.1177_2050640620967898 - Supplemental material for A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group

Author

Josbert J Keller, Ooijevaar, Rogier E, Hvas, Christian L, Terveer, Elisabeth M, Lieberknecht, Simone C, Högenauer, Christoph, Arkkila, Perttu, Sokol, Harry, Gridnyev, Oleksiy, Mégraud, Francis, Kump, Patrizia K, Nakov, Radislav, Goldenberg, Simon D, Satokari, Reetta, Tkatch, Sergiy, Sanguinetti, Maurizio, Cammarota, Giovanni, Dorofeev, Andrey, Gubska, Olena, Ianiro, Gianluca, Mattila, Eero, Arasaradnam, Ramesh P, Sarin, Shiv K, Sood, Ajit, Putignani, Lorenza, Alric, Laurent, Simon MD Baunwall, Kupcinskas, Juozas, Link, Alexander, Goorhuis, Abraham G, Verspaget, Hein W, Cyriel Ponsioen, Hold, Georgina L, Tilg, Herbert, Zain Kassam, Kuijper, Ed J, Gasbarrini, Antonio, Mulder, Chris JJ, Williams, Horace RT, and Vehreschild, Maria JGT

Subjects
FOS: Clinical medicine, FOS: Biological sciences, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 110308 Geriatrics and Gerontology, 69999 Biological Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-1-ueg-10.1177_2050640620967898 for A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group by Josbert J Keller, Rogier E Ooijevaar, Christian L Hvas, Elisabeth M Terveer, Simone C Lieberknecht, Christoph Högenauer, Perttu Arkkila, Harry Sokol, Oleksiy Gridnyev, Francis Mégraud, Patrizia K Kump, Radislav Nakov, Simon D Goldenberg, Reetta Satokari, Sergiy Tkatch, Maurizio Sanguinetti, Giovanni Cammarota, Andrey Dorofeev, Olena Gubska, Gianluca Ianiro, Eero Mattila, Ramesh P Arasaradnam, Shiv K Sarin, Ajit Sood, Lorenza Putignani, Laurent Alric, Simon MD Baunwall, Juozas Kupcinskas, Alexander Link, Abraham G Goorhuis, Hein W Verspaget, Cyriel Ponsioen, Georgina L Hold, Herbert Tilg, Zain Kassam, Ed J Kuijper, Antonio Gasbarrini, Chris JJ Mulder, Horace RT Williams and Maria JGT Vehreschild in United European Gastroenterology Journal

Published
2020
Full Text
View/download PDF

20. The influence of gastroesophageal reflux disease comorbidity on biochemical markers, data of ambulatory blood pressure monitoring and echocardioscopy in patients with hypertension

Author

FADIEIENKO GALYNA DMYTRIVNA and GRIDNYEV OLEKSIY IEVGENIOVYCH

Subjects
GASTROESOPHAGEAL REFLUX DISEASE,HYPERTENSION,AMBULATORY BLOOD PRESSURE MONITORING,ECHOCARDIOSCOPY,LIPID PROFILE,LIPID PEROXIDATION,APELIN, lipids (amino acids, peptides, and proteins)
Abstract

The article presents the characteristics of biochemical parameters, data of daily profile of blood pressure and echocardioscopy in patients with comorbidity of gastroesophageal reflux disease and hypertension. Particular attention is paid to the characteristics of the “lipid peroxidation-antioxidant protection.”

Published
2015

21. A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group

Author

Keller, Josbert J, Ooijevaar, Rogier E, Hvas, Christian L, Terveer, Elisabeth M, Lieberknecht, Simone C, Högenauer, Christoph, Arkkila, Perttu, Sokol, Harry, Gridnyev, Oleksiy, Mégraud, Francis, Kump, Patrizia K, Nakov, Radislav, Goldenberg, Simon D, Satokari, Reetta, Tkatch, Sergiy, Sanguinetti, Maurizio, Cammarota, Giovanni, Dorofeev, Andrey, Gubska, Olena, Ianiro, Gianluca, Mattila, Eero, Arasaradnam, Ramesh P, Sarin, Shiv K, Sood, Ajit, Putignani, Lorenza, Alric, Laurent, Baunwall, Simon MD, Kupcinskas, Juozas, Link, Alexander, Goorhuis, Abraham G, Verspaget, Hein W, Ponsioen, Cyriel, Hold, Georgina L, Tilg, Herbert, Kassam, Zain, Kuijper, Ed J, Gasbarrini, Antonio, Mulder, Chris JJ, Williams, Horace RT, and Vehreschild, Maria JGT

Abstract

Background Fecal microbiota transplantation is an emerging therapeutic option, particularly for the treatment of recurrent Clostridioides difficileinfection. Stool banks that organise recruitment and screening of feces donors are being embedded within the regulatory frameworks described in the European Union Tissue and Cells Directive and the technical guide to the quality and safety of tissue and cells for human application, published by the European Council.Objective Several European and international consensus statements concerning fecal microbiota transplantation have been issued. While these documents provide overall guidance, we aim to provide a detailed description of all processes that relate to the collection, handling and clinical application of human donor stool in this document.Methods Collaborative subgroups of experts on stool banking drafted concepts for all domains pertaining to stool banking. During a working group meeting in the United European Gastroenterology Week 2019 in Barcelona, these concepts were discussed and finalised to be included in our overall guidance document about fecal microbiota transplantation.Results A guidance document for all domains pertaining to stool banking was created. This document includes standard operating manuals for several processes involved with stool banking, such as handling of donor material, storage and donor screening.Conclusion The implementation of fecal microbiota transplantation by stool banks in concordance with our guidance document will enable quality assurance and guarantee the availability of donor feces preparations for patients.

Published
2024
Full Text
View/download PDF

22. The influence of gastroesophageal reflux disease comorbidity on biochemical markers, data of ambulatory blood pressure monitoring and echocardioscopy in patients with hypertension.

Author

Dmytrivna, Fadieienko Galyna and Ievgeniovych, Gridnyev Oleksiy

Subjects
*AMBULATORY blood pressure monitoring, *GASTROESOPHAGEAL reflux, *BIOMARKERS, *PATIENT monitoring, *HYPERTENSION
Abstract

The article presents the characteristics of biochemical parameters, data of daily profile of blood pressure and echocardioscopy in patients with comorbidity of gastroesophageal reflux disease and hypertension. Particular attention is paid to the characteristics of the "lipid peroxidation-antioxidant protection.". [ABSTRACT FROM AUTHOR]

Published
2015

23. PAPEL DEL USO DE PROBIÓTICOS EN LA EFECTIVIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI(HP-EUREG)

Author

Casas, Diego, Alcedo, Javier, Lafuente, Miguel, López, F. Javier, Pérez-Aisa, Angeles, Pavoni, Matteo, Saracino, Ilaria Maria, Tepes, Bojan, Jonaitis, Laimas, Castro-Fernández, Manuel, Carrasco, Manuel Pabón, Huerga, Alma Keco-, Voynovan, Irina, Bujanda, Luis, Lucendo, Alfredo J., Jurecic, Natasa Brglez, Denkovski, Maja, Phull, Perminder S., Rodrigo, Luis, Lanas, Angel, Martínez-Domínguez, Samuel J., Alfaro, Enrique, Fadieienko, Galina D, Huguet, José M., Bordin, Dmitry S., Gasbarrini, Antonio, Kupcinskas, Juozas, Babayeva, Gülüstan, Gridnyev, Oleksiy, Leja, Mrcis, Rokkas, Theodore, Marcos-Pinto, Ricardo, Lerang, Frode, Boltin, Doron, Papp, Veronika, Tonki, Ante, Smith, Sinead M., Simsek, Halis, Venerito, Marino, Boyanova, Lyudmila, Milivojevic, Vladimir, Kunovsky, Lumir, Matysiak-Budnik, Tamara, Marlicz, Wojciech, Doulberis, Michael, Cano-Català, Anna, Hernández, Luis, Moreira, Leticia, Nyssen, Olga P., Megraud, Francis, Morain, Colm O., and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

24. 131 - PAUTAS Y EFECTIVIDAD DE LAS TERAPIAS CUÁDRUPLES CON BISMUTO EN EUROPA: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI(HP-EUREG)

Author

Calvet, Xavier, Gené, Emili, Olmedo, Llum, Bordin, Dmitry, García-Morales, Natalia, Hernández, Luis, Gridnyev, Oleksiy, Kupinskas, Juozas, Gasbarrini, Antonio, Boltin, Doron, Babayeva, Gulustan, Pinto, Ricardo Marcos, Tepes, Bojan, Buzas, Gyorgy M, Papp, Veronika, Simsek, Halis, Cano-Català, Anna, Moreira, Leticia, Puig, Ignasi, Nyssen, Olga P., Mégraud, Francis, O’Morain, Colm, and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

25. 135 - TENDENCIAS DE PRESCRIPCIÓN DE TRATAMIENTOS ERRADICADORES Y DE SU EFECTIVIDAD EN PACIENTES NAÏVEA LO LARGO DE 10 AÑOS (2013-2022) EN EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI(HP-EUREG)

Author

Nyssen, Olga P., Jonaitis, Laimas, Pérez-Aísa, Ángeles, Vaira, Dino, Fiorini, Giulia, Saracino, Ilaria Maria, Tepes, Bojan, Bordin, Dmitry, Huerga, Alma Keco-, Castro-Fernández, Manuel, Lucendo, Alfredo, Vologzhanina, Liudmila, Bujanda, Luis, Jurecic, Natasa Brglez, Denkovski, Maja, Lanas, Angel, Martínez-Dominguez, Samuel, Alfaro, Enrique, Leja, Marcis, Bumane, Renate, Mammadov, Emin, Babayeva, Gulustan, Mahmudov, Umud, Caldas, María, Rodrigo, Luis, Lerang, Frode, Fadieienko, Galyna, Abdulkhakov, Rustam, Malavés, Jose María Huguet, Zaytsev, Oleg, Ilchishina, Tatiana, Fernández-Salazar, Luis, Alcaide, Noelia, Velayos, Benito, Sarsenbaeva, Aiman Silkanovna, Bakulin, Igor, Gravina, Antonietta G., Romano, Marco, Perona, Mónica, Alekseenko, Sergey, Barrio, Jesús, Areia, Miguel, Nuñez, Óscar, Bogomolov, Pavel, Rodríguez, Blas José Gómez, Cajal, Manuel Dominguez-, Camarero, Judith Gomez, Moreno, Manuel Jiménez, Georgopoulos, Sotirios, Notari, Pedro Almela, Tonkic, Ante, Pellicano, Rinaldo, Simsek, Halis, Kunovský, Lumír, Gasbarrini, Antonio, Bote, Jose Maria Botargues, Buzas, Gyorgy M, Fernández-Bermejo, Miguel, Phull, Perminder, Venerito, Marino, Malfertheiner, Peter, Rosania, Rosa, Link, Alexander, Iyo, Eduardo, Kupinskas, Juozas, Shvets, Oleg, Pinto, Ricardo Marcos, Rokkas, Theodore, Simsek, Ilkay, Smith, Sinead, Boltin, Doron, Lamarque, Dominique, Dobru, Daniela, Marlicz, Wojciech, Milivojevic, Vladimir, Boyanova, Lyudmila, Lamy, Vincent, Doulberis, Michael, Bytzer, Peter, Capelle, Lisette, Gridnyev, Oleksiy, Ristimaki, Ari, Cano-Català, Anna, Puig, Ignasi, Mégraud, Francis, O’Morain, Colm, and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

26. 133 - PATRÓN DE PRESCRIPCIÓN DE PROBIÓTICOS ADYUVANTES A LA TERAPIA ERRADICADORA FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI(HP-EUREG)

Author

Casas, Diego, Alcedo, Javier, Lafuente, Miguel, López, F. Javier, Pérez-Aisa, Angeles, Pavoni, Matteo, Saracino, Ilaria Maria, Tepes, Bojan, Jonaitis, Laimas, Castro-Fernández, Manuel, Pabón-Carrasco, Manuel, Keco-Huerga, Alma, Voynovan, Irina, Bujanda, Luis, Lucendo, Alfredo J., Jurecic, Natasa Brglez, Denkovski, Maja, Phull, Perminder S., Rodrigo, Luis, Lanas, Angel, Martínez-Domínguez, Samuel J., Alfaro, Enrique, Fadieienko, Galina D, Huguet, José M., Bordin, Dmitry S., Gasbarrini, Antonio, Kupcinskas, Juozas, Babayeva, Gülüstan, Gridnyev, Oleksiy, Leja, Mrcis, Rokkas, Theodore, Marcos-Pinto, Ricardo, Lerang, Frode, Boltin, Doron, Papp, Veronika, Tonki, Ante, Smith, Sinead M., Simsek, Halis, Venerito, Marino, Boyanova, Lyudmila, Milivojevic, Vladimir, Kunovsky, Lumir, Matysiak-Budnik, Tamara, Marlicz, Wojciech, Doulberis, Michael, Cano-Català, Anna, Hernández, Luis, Moreira, Leticia, Nyssen, Olga P., Megraud, Francis, Morain, Colm O., and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

27. 130 - COMPARACIÓN DE LA EFECTIVIDAD DE LOS TRATAMIENTOS ERRADICADORES MÁS FRECUENTES ENTRE LAS POBLACIONES MÁS MAYORES Y MÁS JÓVENES DE EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI(HP-EUREG)

Author

Jonaitis, Paulius, Nyssen, Olga P., Saracino, Ilaria Maria, Fiorini, Giulia, Vaira, Dino, Pérez-Aísa, Ángeles, Tepes, Bojan, Castro-Fernández, M., Pabón-Carrasco, Manuel, Keco-Huerga, Alma, Voynovan, Irina, Lucendo, Alfredo J, Lanas, Ángel, Martínez-Domínguez, Samuel J, Almajano, Enrique Alfaro, Rodrigo, Luis, Vologzanina, Ludmila, Jurecic, Natasa Brglez, Denkovski, Maja, Bujanda, Luis, Mahmudov, Umud, Leja, Mrcis, Lerang, Frode, Babayeva, Gülüstan, Bordin, Dmitry S., Gasbarrini, Antonio, Kupcinskas, Juozas, Gridnyev, Oleksiy, Rokkas, Theodore, Marcos-Pinto, Ricardo, Phull, Perminder S., Smith, Sinead M., Tonki, Ante, Boltin, Doron, Buzás, György Miklós, Kunovský, Lumír, imek, Halis, Matysiak-Budnik, Tamara, Milivojevic, Vladimir, Marlicz, Wojciech, Venerito, Marino, Boyanova, Lyudmila, Doulberis, Michael, Capelle, Lisette G., Cano-Català, Anna, Moreira, Leticia, Mégraud, Francis, O’Morain, Colm, Gisbert, Javier P., and Jonaitis, Laimas

Published
2023
Full Text
View/download PDF

28. 127 - IMPACTO DEL USO DE PROBIÓTICOS EN LA SEGURIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI(HP-EUREG)

Author

Casas, Diego, Alcedo, Javier, Lafuente, Miguel, López, F. Javier, Pérez-Aisa, Angeles, Pavoni, Matteo, Saracino, Ilaria Maria, Tepes, Bojan, Jonaitis, Laimas, Castro-Fernández, Manuel, Pabón-Carrasco, Manuel, Keco-Huerga, Alma, Voynovan, Irina, Bujanda, Luis, Lucendo, Alfredo J., Jurecic, Natasa Brglez, Denkovski, Maja, Phull, Perminder S., Rodrigo, Luis, Lanas, Angel, Martínez-Domínguez, Samuel J., Alfaro, Enrique, Fadieienko, Galina D., Huguet, Jose M., Bordin, Dmitry S., Gasbarrini, Antonio, Kupcinskas, Juozas, Babayeva, Gülüstan, Gridnyev, Oleksiy, Leja, Mrcis, Rokkas, Theodore, Marcos-Pinto, Ricardo, Lerang, Frode, Boltin, Doron, Papp, Veronika, Tonki, Ante, Smith, Sinead M., Simsek, Halis, Venerito, Marino, Boyanova, Lyudmila, Milivojevic, Vladimir, Kunovsky, Lumir, Matysiak-Budnik, Tamara, Marlicz, Wojciech, Doulberis, Michael, Cano-Català, Anna, Hernández, Luis, Moreira, Leticia, Nyssen, Olga P., Megraud, Francis, Morain, Colm O., and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

29. Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg).

Author

Martínez-Domínguez SJ, Nyssen OP, Lanas Á, Alfaro E, Jonaitis L, Mahmudov U, Voynovan I, Gülüstan B, Rodrigo L, Fiorini G, Perez-Aisa Á, Tejedor-Tejada J, Tepes B, Vologzanina L, Mammadov E, Lerang F, Oğlu QFV, Bakulina NV, Abdulkhakov R, Tatiana I, Butler TJ, Sarsenbaeva AS, Bumane R, Lucendo AJ, Romano M, Bujanda L, Abdulkhakov SR, Zaytsev O, Pabón-Carrasco M, Keco-Huerga A, Denkovski M, Huguet JM, Perona M, Núñez Ó, Pavoni M, Fadieienko G, Alekseenko S, Smith SM, Hernández L, Kupcinskas J, Bordin DS, Leja M, Gasbarrini A, Gridnyev O, Cano-Català A, Parra P, Moreira L, Mégraud F, O'Morain C, and Gisbert JP

Subjects
Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult, Drug Therapy, Combination, Europe, Prospective Studies, Treatment Outcome, Anti-Bacterial Agents therapeutic use, Helicobacter Infections drug therapy, Helicobacter pylori drug effects
Abstract

Background: The influence of indications for Helicobacter pylori investigation on prescriptions and effectiveness is unknown. The aim of the study was to assess the impact of indications for H. pylori investigation on prescriptions, effectiveness, compliance, and tolerance., Methods: International, prospective, non-interventional registry of the management of H. pylori infection by European gastroenterologists (Hp-EuReg). Treatment-näive patients registered from 2013 to 2023 at e-CRF AEG-REDCap were analyzed. The effectiveness was assessed by modified intention-to-treat analysis., Results: Overall, 53,636 treatment-naïve cases from 34 countries were included. Most frequent indications were: dyspepsia with normal endoscopy (49%), non-investigated dyspepsia (20%), duodenal ulcer (11%), gastric ulcer (7.7%), and gastroesophageal reflux disease (GERD) (2.6%). Therapy effectiveness varied by indication: duodenal ulcer (91%), gastric ulcer (90%), preneoplastic lesions (90%), dyspepsia with normal endoscopy (89%), GERD (88%), and non-investigated dyspepsia (87%). Bismuth-metronidazole-tetracycline and clarithromycin-amoxicillin-bismuth quadruple therapies achieved 90% effectiveness in all indications except GERD. Concomitant clarithromycin-amoxicillin-tinidazole/metronidazole reached 90% cure rates except in patients with non-investigated dyspepsia; whereas sequential clarithromycin-amoxicillin-tinidazole/metronidazole proved optimal (≥90%) in patients with gastric ulcer only. Adverse events were higher in patients treated for dyspepsia with normal endoscopy and duodenal ulcer compared with the remaining indications (23% and 28%, p < 0.001). Therapeutic compliance was higher in patients with duodenal ulcer and preneoplastic lesions (98% and 99%, p < 0.001)., Conclusion: In Europe, patients with gastric or duodenal ulcers and preneoplastic lesions showed higher H. pylori treatment effectiveness. Bismuth and non-bismuth quadruple therapies achieved optimal results in almost all indications., Trial Registration: ClinicalTrials.gov identifier: NCT02328131., (© 2024 The Author(s). Helicobacter published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

30. Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management.

Author

Huguet JM, Ferrer-Barceló L, Suárez P, Barcelo-Cerda S, Sempere J, Saracino IM, Fiorini G, Vaira D, Pérez-Aísa Á, Jonaitis L, Tepes B, Castro-Fernandez M, Pabón-Carrasco M, Keco-Huerga A, Voynovan I, Lucendo AJ, Lanas Á, Martínez-Domínguez SJ, Alfaro Almajano E, Rodrigo L, Vologzanina L, Bordin DS, Gasbarrini A, Babayeva G, Lerang F, Leja M, Kupčinskas J, Rokkas T, Marcos-Pinto R, Meštrović A, Gridnyev O, Phull PS, Smith SM, Boltin D, Buzás GM, Kral J, Şimşek H, Matysiak-Budnik T, Milivojevic V, Marlicz W, Venerito M, Boyanova L, Doulberis M, Capelle LG, Cano-Català A, Moreira L, Nyssen OP, Mégraud F, O'Morain C, and Gisbert JP

Subjects
Humans, Male, Female, Middle Aged, Prospective Studies, Europe, Adult, Treatment Outcome, Clarithromycin therapeutic use, Aged, Dyspepsia drug therapy, Dyspepsia microbiology, Metronidazole therapeutic use, Metronidazole administration & dosage, Bismuth therapeutic use, Bismuth administration & dosage, Bismuth adverse effects, Helicobacter Infections drug therapy, Helicobacter pylori drug effects, Medication Adherence statistics & numerical data, Proton Pump Inhibitors therapeutic use, Proton Pump Inhibitors administration & dosage, Registries, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents adverse effects, Drug Therapy, Combination, Amoxicillin therapeutic use, Amoxicillin administration & dosage
Abstract

Background: Adherence to Helicobacter pylori (H. pylori) eradication treatment is a cornerstone for achieving adequate treatment efficacy., Objective: To determine which factors influence compliance with treatment., Methods: A systematic prospective non-interventional registry (Hp-EuReg) of the clinical practice of European gastroenterologists. Compliance was considered adequate if ≥90% drug intake. Data were collected until September 2021 using the AEG-REDCap e-CRF and were subjected to quality control. Modified intention-to-treat analyses were performed. Multivariate analysis carried out the factors associated with the effectiveness of treatment and compliance., Results: Compliance was inadequate in 646 (1.7%) of 38,698 patients. The non-compliance rate was higher in patients prescribed longer regimens (10-, 14-days) and rescue treatments, patients with uninvestigated dyspepsia/functional dyspepsia, and patients reporting adverse effects. Prevalence of non-adherence was lower for first-line treatment than for rescue treatment (1.5% vs. 2.2%; p < 0.001). Differences in non-adherence in the three most frequent first-line treatments were shown: 1.1% with proton pump inhibitor + clarithromycin + amoxicillin; 2.3% with proton pump inhibitor clarithromycin amoxicillin metronidazole; and 1.8% with bismuth quadruple therapy. These treatments were significantly more effective in compliant than in non-compliant patients: 86% versus 44%, 90% versus 71%, and 93% versus 64%, respectively (p < 0.001). In the multivariate analysis, the variable most significantly associated with higher effectiveness was adequate compliance (odds ratio, 6.3 [95%CI, 5.2-7.7]; p < 0.001)., Conclusions: Compliance with Helicobacter pylori eradication treatment is very good. Factors associated with poor compliance include uninvestigated/functional dyspepsia, rescue-treatment, prolonged treatment regimens, the presence of adverse events, and the use of non-bismuth sequential and concomitant treatment. Adequate treatment compliance was the variable most closely associated with successful eradication., (© 2024 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)

Published
2024
Full Text
View/download PDF

31. Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013-2022: Data from the European Registry on H. pylori Management (Hp-EuReg).

Author

Nyssen OP, Pratesi P, Spínola MA, Jonaitis L, Pérez-Aísa Á, Vaira D, Saracino IM, Pavoni M, Fiorini G, Tepes B, Bordin DS, Voynovan I, Lanas Á, Martínez-Domínguez SJ, Alfaro E, Bujanda L, Pabón-Carrasco M, Hernández L, Gasbarrini A, Kupcinskas J, Lerang F, Smith SM, Gridnyev O, Leja M, Rokkas T, Marcos-Pinto R, Meštrović A, Marlicz W, Milivojevic V, Simsek H, Kunovsky L, Papp V, Phull PS, Venerito M, Boyanova L, Boltin D, Niv Y, Matysiak-Budnik T, Doulberis M, Dobru D, Lamy V, Capelle LG, Nikolovska Trpchevska E, Moreira L, Cano-Català A, Parra P, Mégraud F, O'Morain C, Ortega GJ, Gisbert JP, and On Behalf Of The Hp-EuReg Investigators

Abstract

The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. Data collection : All first-line empirical treatments registered at AEGREDCap in the European Registry on Helicobacter pylori management (Hp-EuReg) from June 2013 to November 2022. A Boruta method determined the "most important" variables related to treatment effectiveness. Data clustering was performed through multi-correspondence analysis of the resulting six most important variables for every year in the 2013-2022 period. Based on 35,852 patients, the average overall treatment effectiveness increased from 87% in 2013 to 93% in 2022. The lowest effectiveness (80%) was obtained in 2016 in cluster #3 encompassing Slovenia, Lithuania, Latvia, and Russia, treated with 7-day triple therapy with amoxicillin-clarithromycin (92% of cases). The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth-quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin-amoxicillin-metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. Cluster analysis allowed for the identification of patients in homogeneous treatment groups assessing the effectiveness of different first-line treatments depending on therapy scheme, adherence, country, and prescription year.

Published
2023
Full Text
View/download PDF

32. Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management.

Author

García-Morales N, Pérez-Aísa Á, Fiorini G, Tepes B, Castro-Fernández M, Lucendo A, Voynovan I, Bujanda L, Garre A, Rodrigo L, Martínez Domínguez SJ, Denkovski M, Huguet Malavés JM, Jonaitis L, Bumane R, Zaytsev O, Mata Romero P, Barrio J, Fernández-Salazar L, Sarsenbaeva AS, Ortiz Polo I, Alekseenko S, Saracino IM, Vaira D, Keco-Huerga A, Bordin D, Gasbarrini A, Lerang F, Rokkas T, Kupčinskas J, Leja M, Babayeva G, Marcos Pinto R, Tonkić A, Smith S, Phull P, Buzas GM, Simsek H, Boltin D, Gridnyev O, Venerito M, Milivojevic V, Torà N, Cano-Català A, Moreira L, Nyssen OP, Mégraud F, O'Morain C, Gisbert JP, Puig I, and On Behalf Of Hp-EuReg Investigators

Abstract

Background and Aims: Several methods are available to diagnose Helicobacter pylori infection. Our objective was to evaluate the tests used for both the initial diagnosis and the confirmation of eradication after treatment in Europe., Methods: The European Registry on the management of Helicobacter pylori infection is an international, multicentre, prospective, non-interventional registry aiming to evaluate the management of Helicobacter pylori -infected patients in Europe. Countries with at least 100 cases registered from June 2013 to April 2021, and with a validated diagnostic method were analysed. Data were quality reviewed., Results: A total of 34,920 adult patients from 20 countries were included (mean age 51 years; 61% women). To establish the initial diagnosis, invasive tests were performed in 19,801 (71%) patients, non-invasive in 11,369 (41%), and both in 3437 (12%). The most frequent were histology (n = 11,885; 43%), a rapid urease test (n = 10,636; 38%) and an urea breath test (n = 7577; 27%). According to the age, invasive tests were indicated in 11,179 (77%) ≥50 years, and in 8603 (65%) <50 years. Depending on the country, the use of invasive tests ranged from 29-99% in <50 years to 60-99% in ≥50. Most of the tests used to confirm eradication were non-invasive (n = 32,540; 93%), with the urea breath test being the most frequent (n = 32,540; 78%). In 2983 (9%) post-treatment tests, histology (n = 1887; 5%) or a rapid urease test (n = 1223; 4%) were performed., Conclusion: A great heterogeneity was observed for the initial diagnosis and confirmation of the eradication. The reasons for the apparent lack of adherence to the clinical guidelines should be further explored.

Published
2023
Full Text
View/download PDF

33. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg).

Author

Burgos-Santamaría D, Nyssen OP, Gasbarrini A, Vaira D, Pérez-Aisa Á, Rodrigo L, Pellicano R, Keco-Huerga A, Pabón-Carrasco M, Castro-Fernandez M, Boltin D, Barrio J, Phull P, Kupcinskas J, Jonaitis L, Ortiz-Polo I, Tepes B, Lucendo AJ, Huguet JM, Areia M, Jurecic NB, Denkovski M, Bujanda L, Ramos-San Román J, Cuadrado-Lavín A, Gomez-Camarero J, Jiménez Moreno MA, Lanas A, Martinez-Dominguez SJ, Alfaro E, Marcos-Pinto R, Milivojevic V, Rokkas T, Leja M, Smith S, Tonkić A, Buzás GM, Doulberis M, Venerito M, Lerang F, Bordin DS, Lamy V, Capelle LG, Marlicz W, Dobru D, Gridnyev O, Puig I, Mégraud F, O'Morain C, and Gisbert JP

Abstract

Objective: To evaluate the use, effectiveness and safety of Helicobacter pylori empirical rescue therapy in third and subsequent treatment lines in Europe., Design: International, prospective, non-interventional registry of the clinical practice of European gastroenterologists. Data were collected and quality reviewed until October 2021 at Asociación Española de Gastroenterología-Research Electronic Data Capture. All cases with three or more empirical eradication attempts were assessed for effectiveness by modified intention-to-treat and per-protocol analysis., Results: Overall, 2144 treatments were included: 1519, 439, 145 and 41 cases from third, fourth, fifth and sixth treatment lines, respectively. Sixty different therapies were used; the 15 most frequently prescribed encompassed >90% of cases. Overall effectiveness remained <90% in all therapies. Optimised treatments achieved a higher eradication rate than non-optimised (78% vs 67%, p<0.0001). From 2017 to 2021, only 44% of treatments other than 10-day single-capsule therapy used high proton-pump inhibitor doses and lasted ≥14 days. Quadruple therapy containing metronidazole, tetracycline and bismuth achieved optimal eradication rates only when prescribed as third-line treatment, either as 10-day single-capsule therapy (87%) or as 14-day traditional therapy with tetracycline hydrochloride (95%). Triple amoxicillin-levofloxacin therapy achieved 90% effectiveness in Eastern Europe only or when optimised. The overall incidence of adverse events was 31%., Conclusion: Empirical rescue treatment in third and subsequent lines achieved suboptimal effectiveness in most European regions. Only quadruple bismuth-metronidazole-tetracycline (10-day single-capsule or 14-day traditional scheme) and triple amoxicillin-levofloxacin therapies reached acceptable outcomes in some settings. Compliance with empirical therapy optimisation principles is still poor 5 years after clinical practice guidelines update., Trial Registration Number: NCT02328131., Competing Interests: Competing interests: OPN has received research funding from Mayoly and Allergan. JPG has served as speaker, consultant and advisory member for or has received research funding from Mayoly, Allergan, Diasorin, Gebro Pharma and Richen. MC-F has received retribution from Allergan for formative actions. AP-A has received retribution from Allergan and Mylan for formative actions. Laimas Jonaitis has served as speaker for KRKA. AL has served as a consultant to Bayer., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results